Interferon-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells

作     者：Yuan-Qin Yang Wen-Jie Dong Xiao-Fei Yin Yan-Ni XU Yu Yang Jiao-Jiao Wang Su-Jing Yuan Jing Xiao Jonathan Howard DeLong Liang Chu Hai-Neng Xu Xiu- Mei Zhou Ru-Wei Wang Ling Fang Xin-Yuan Liu Kang-Jian Zhang 

作者机构：Xinyuan Institute of Medicine and Biotechnology Zhejiang Sci-Tech University Hangzhou 310018 China State Key Laboratory of Cell Biology Shanghai Institute of Biochemistry and Cell Biology Shanghai Institutes for Biological Sciences Chinese Academy of Sciences Shanghai 200031 China Sichuan Huiyang Life Science and Technology Corp. Chengdu 610021 China College of Life Sciences Northwest Agriculture and Forestry University Yangling 712100 China Central China Normal University Wuhan 430079 China Department of Pathobiology School of Veterinary Medicine University of Pennsylvania Philadelphia PA 19104 USA Department of Radiation Oncology University of Pennsylvania Perelman School of Medicine 3400 Civic Center Blvd. Philadelphia PA 19104 USA Zhejiang Conba Pharmaceutical Co. Ltd Hangzhou 310018 China 

出 版 物：《Protein & Cell》 (蛋白质与细胞（英文版）)

年 卷 期：2016年第7卷第7期

页      面：538-543页

核心收录：

学科分类：090602[农学-预防兽医学] 1002[医学-临床医学] 09[农学] 0906[农学-兽医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by Sichuan Science and Technology Project Shanghai Institutes for Biological Science, Chinese Academy of Sciences & Sichuan Huiyang Life Science and Technology Corp Research Program 国家973计划 Zhejiang Sci-Tech University Grant the Sino-American Joint Laboratory between Conba Group and Zhejiang Sci-Tech University 

主　　题：tumor immune expressed 

摘      要：Dear Editor, PD-L1, also known as CD274, plays a vital role in tumor cell related immune escape. It can be expressed on the cell surface of many solid tumors （Brahmer et al., 2012） and inhibits T cell proliferation and cytokine production by bind- ing to the Tcell surface receptor programmed death 1 （PD-1） or B7-1 （McClanahan et al., 2015）. In 2013, targeting PD-1/ PD-L1 signaling for cancer immunotherapy was selected as the No.1 scientific breakthrough of the year by the editors of Science. Interferons （IFNs） are a group of pleiotropic cytokines, demonstrated anti-viral, anti-tumor, and immune regulatory functions （York et al., 2015）. Type I interferon binds a heterodimeric receptor composed of IFNAR1 and IFNAR2. This activates a canonical JAK/STAT signaling pathway that ultimately induces a set of interferon-stimulated genes to exert its biological activity （Ejlerskov et al., 2015）. Recently, PD-L1 was reported to be downstream of IFN signaling in human oral squamous carcinoma, melanoma, and human acute myeloid leukemia blast cells （Chen et al., 2012; Furuta et al., 2014; Kronig et al., 2014）.